PROGRAM OVERVIEW
Session I
Session II
Session I

Presented by: Mrs. Myriam Hakim (UAE), Dr. Alfadel Alshaibani (KSA), Prof. Pietro Quaglino (Italy), Dr. Mohsen Al Zahrani (KSA), Dr. Youssef Binamer (KSA) & Dr. Mubarak Al Mansour (KSA)
Moderated by: Dr. Ayman Hijazi (KSA)

Agenda

  • 19:30-19:40

    Kyowa Kirin Pharma: Partner in the Oncology & Hematology Field
    Presented by Mrs. Myriam Hakim (UAE)

  • 19:40-19:55

    CTCL – Beyond Skin Deep
    Presented by Dr. Alfadel Alshaibani (KSA)

  • 19:55-20:15

    Pathophisiology & Diagnosis Journey
    Presented by Prof. Pietro Quaglino (Italy)

  • 20:15-20:35

    You Make the Call: Early MF Management Debate: Skin or Blood? (Poll Session)
    Presented by Dr. Mohsen Al Zahrani (KSA), Dr. Youssef Binamer (KSA)

  • 20:35-20:50

    The Role of Blood Involvement in the Pathogenesis of CTCL
    Presented by Dr. Mubarak Al Mansour (KSA)

  • 20:50-21:00

    Panel Discussion
    Questions and Answers will open to the Audience

Faculty

Dr. Alfadel AlShaibani
Consultant Hematologist
King Faisal Specialist Hospital and Research Center (KFSHRC)
Riyadh, Kingdom of Saudi Arabia

Dr. Mohsen Al Zahrani
Consultant Hematologist & Head, Division of the Stem Cell Transplant & Cellular Therapy
King Abdulaziz Medical City
Riyadh, Kingdom of Saudi Arabia

Dr. Mubarak Al Mansour
Acting Chairman, Oncology Department at Princess Noorah Oncology Center
King Abdulaziz Medical City, MNG-HA
Jeddah, Kingdom of Saudi Arabia

Mrs. Myriam Hakim
Cluster General Manager
Kyowa Kirin

Prof. Pietro Quaglino
Associate Professor
University of Turin
Turin, Italy

Dr. Youssef Binamer
Chairman, Dermatology Department
King Faisal Specialist Hospital
Riyadh, Kingdom of Saudi Arabia

Session II

Presented by: Dr. Takeshi Takahashi (Japan), Prof. Reyad Dada (KSA), Dr. Steven Horwitz (USA), Dr. Riad Fakih (KSA) & Dr. Steven Horwitz (USA)
Moderated by: Dr. John Apostolidis (KSA)

Agenda

  • 21:00-21:10

    Poteligent Technology and Clinical Development
    Presented by Dr. Takeshi Takahashi (Japan)

  • 21:10-21:20

    Poteligeo (Mogamulizumab): A New Option in the Management of CTCL
    Presented by Prof. Reyad Dada (KSA)

  • 21:20-21:35

    MAVORIC: Largest Randomised Phase III Trial in CTCL
    Presented by Dr. Steven Horwitz (USA)

  • 21:35-21:50

    Poteligeo (Mogamulizumab) Efficacy: Post-Hoc Analysis
    Presented by Dr. Steven Horwitz (USA)

  • 21:50-22:00

    Real-World Experience with Poteligeo
    Presented by Dr. Riad Fakih (KSA) & Dr. Steven Horwitz (USA)

  • 22:00-22:10

    Q&A

  • 22:10-22:15

    Closing Remarks

Faculty

Prof. Reyad Dada
Consultant Medical Oncologist
King Faisal Specialist Hospital and Research Center
Jeddah, Kingdom of Saudi Arabia

Dr. Riad El Fakih
Head, Clinical Research Department and Associate Professor
Alfaisal University Consultant Hematologist
King Faisal Specialist Hospital and Research Centre
Riyadh, Kingdom of Saudi Arabia

Dr. Steven Horwitz
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, United States of America

Dr. Takeshi Takahashi
Global Medical Affairs
Kyowa Kirin
Tokyo, Japan